https://www.onclive.com/view/tki-immunotherapy-combinations-expand-rcc-treatment-options
0
0
2/12/23 at 11:06am
Organization
OncLive
47 words
0
Comments
Rohit Kumar, MD, discusses the benefits of TKI/immunotherapy doublets in renal cell carcinoma, unmet needs regarding future research with triplet therapies in the frontline setting, and how hypoxia inducible factor inhibitors may play a role in the treatment…
You are the first to view
Create an account
or login to join the discussion